Kalaris Therapeutics Inc
KLRS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $42 | $88 | $101 | $118 |
| Short-Term Investments | $35 | $0 | $0 | $0 |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $1 | $3 | $1 | $0 |
| Total Curr. Assets | $78 | $92 | $102 | $119 |
| Property Plant & Equip (Net) | $2 | $0 | $0 | $0 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $1 | $1 | $1 | $0 |
| Total NC Assets | $3 | $1 | $1 | $0 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $81 | $93 | $103 | $119 |
| Liabilities | – | – | – | – |
| Payables | $0 | $4 | $2 | $0 |
| Short-Term Debt | $0 | $0 | $0 | $0 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $5 | $4 | $5 | $5 |
| Total Curr. Liab. | $6 | $8 | $7 | $5 |
| LT Debt | $1 | $0 | $0 | $0 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $32 | $32 | $32 | $0 |
| Total NC Liab. | $33 | $32 | $32 | $0 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $2 | $0 | $0 | $0 |
| Total Liabilities | $39 | $40 | $39 | $5 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$150 | -$138 | -$127 | -$715 |
| AOCI | $0 | $0 | $0 | -$0 |
| Other Equity | $192 | $191 | $191 | $828 |
| Total Equity | $42 | $53 | $64 | $113 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $81 | $93 | $103 | $119 |
| Net Debt | -$41 | -$88 | -$101 | -$118 |